Aytu settles derivative shareholder suit; court hearing Jan 13, 2025

AYTU BIOPHARMA, INC

Settlement approval hearing scheduled for January 13, 2025 in Delaware Chancery Court.
Aytu to pay $250,000 in attorneys' fees and $5,000 service award to plaintiff.
Governance enhancements include new independent board member, CEO/Chair separation, enhanced insider trading oversight.
D&O defendants released; claims against Armistice defendants preserved with Aytu remaining neutral.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.